Abstract
Rheumatic heart disease (RHD) is a significant public health problem and Non-adherence to treatment is an important and often unrecognized risk factor for cardiovascular mortality. The study aimed to assess self-reported medication adherence by 8-item Morisky Medication Adherence Scale (MMAS-8) among rheumatic heart disease patients and determine the associated factors. A cross-sectional study was carried out by applying a structured interview to Rheumatic heart disease patients aged 18 or higher in a tertiary hospital in Bangladesh. Among Rheumatic heart disease patients, 63.5% showed medium adherence, 36.5% showed low adherence to medication. Walking habit (P= 0.000), exercise habit (P=0.000), smoking habit (P=0.000), and duration of RHD (P=0.005) found significantly associated with medication adherence. Multiple logistic regression analysis also revealed, don't have walking habit more than 10 minutes at a time (AOR=2.416, 95% CI: 1.212-4.816), don't having exercise habit (AOR=2.420, 95% CI: 1.206 – 4.859), don't having habit of smoking (AOR=0.392, 95% CI: 0.183 – 0.841), duration of RHD for less than 15 (AOR=4.190, 95% CI: 0.851 – 20.631) are independent predictors of adherence. Our study demonstrated medium to low medication adherence in the Morisky Medication Adherence Scale among rheumatic heart disease patients.
 Asian J. Med. Biol. Res. June 2019, 5(3): 186-191
Highlights
Rheumatic heart disease (RHD) is a significant public health problem and leading non-communicable diseases in low- and middle-income countries (LMICs) (Carapetis et al, 2005; Marijon et al, 2012)
Adherence was to medication was measured by the eight-item Morisky Medication Adherence Scale (MMAS-8), translated into Bengali and validated for the present study (Morisky and Green, 1986)
The analysis shows that, walking habit (P= 0.000), exercise habit (Other than walking) (P=0.000), smoking habit (P=0.000), Duration of RHD (P=0.005) statistically significantly associated with medication adherence at 5% significance level
Summary
Rheumatic heart disease (RHD) is a significant public health problem and leading non-communicable diseases in low- and middle-income countries (LMICs) (Carapetis et al, 2005; Marijon et al, 2012). As of 2010 globally, it resulted in 345,000 deaths, and every year, there are about 1.4 million deaths in low- and middle-income countries (Karthikeyan et al, 2012; Paar et al, 2010). According to the WHO, estimates that the cost of nonadherence to drug therapy amounts to 125 million euros per year in Europe (WHO, 2003). Both healthcare provider and patient affect medication adherence, but a positive physician-patient relationship
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
